Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
initiated with an Outperform rating and a $10 price target at Oppenheimer. The firm noted that they find the company to be an upcoming leader in gene therapy for blinding ocular disorders. Oppenheimer highlighted the company's lead asset OCU400, which is currently in Phase 3 trials for retinitis pigmentosa. ?Retinitis pigmentosa is a disease affecting vision. OCU400 targets retinitis pigmentosa with a gene-agnostic approach that could treat multiple genetic mutations, unlike narrower therapies. The firm noted that a potential approval for OCU400 can offer a near-term opportunity for the company to enter a sizable, underserved rare disease market. ?Moreover, the firm also noted that two other programs for progressively degenerative retinal diseases are in development. Therefore, management is expecting three FDA applications over the next 3 years. Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company focused on developing novel gene and cell therapies, biologic
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]Yahoo! Finance
- How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]Yahoo! Finance
- Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]Seeking Alpha
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/20/26 - Form 8-K
- 3/5/26 - Form 3
- 3/4/26 - Form S-8
- OCGN's page on the SEC website